阿托伐他汀对糖尿病肾病患者血清内皮素、心钠素水平的影响

目的：比较糖尿病肾病（DN）患者阿托伐他汀治疗前后心钠素（ANP）、内皮素-1（ET—1）含量的变化，并探讨其临床意义。方法：40例DN患者被随机均分为阿托伐他汀治疗组和常规治疗组，另选20例健康体检者作为正常对照组。分别于治疗前和治疗半年后用放射免疫法检测DN患者血浆ET-1和ANP浓度的变化。结果：与正常对照组比较，DN患者ET-1、ANP水平均明显升高（P〈0．01），阿托伐他汀治疗组血浆ET-1（176±37）ng／L：（246±20）ng／L]、ANP（56±18）ng／L：（102±22）ng／L]水平与治疗前相比显著降低（P〈0．01），且与常规治疗组（218±22）ng／L，（68±28）ng／L]相比有显著降低（P〈0．01）。结论：阿托伐他汀能够降低内皮素-1。心钠素水平，改善糖尿病肾病血管内皮功能。

Effect of atorvastatin on content of plasma atrial natrinretic peptides and endothelin-1 in patients with diabetic nephropathy

Objective： To investigate the effect of atorvastatin on content of plasma atrial natrinretic peptides and endothelin-1 in patients with diabetic nephropathy （DN） . Methods： The 40 DN patients were average divided into atorvastatin treat group, and routine treat group. Another 20 normal persons were regard as normal control group. The contents of plasma ANP and ET- 1 were measured using radioimmunoassary in all subject and treat before and after. Results：The plasma levels of ET-1 and ANP significantly increased in DN patients compared with those in the normal control group （P〈0.01）. After treatment, the plasma levels of ET-1 （176 ± 37） ng/L vs. （246±20） ng/L]and ANP（56±18） ng/L vs. （102±22） ng/L] significantly lower （P〈0.01）than those before therapy in atorvastatin treat group. The plasma levels of ET-1 and ANP in atorvastatin treat group were lower （218±22） ng/L, （ 68±28 ） ng/L] than those in routine treat group after treatment for 6 months （P〈0.01）. Conclusion： Atorvastatin can decrease the plasma levels of ET 1 and ANP, and improve endothelial function in patients with diabetic nephropathy.